Jan. 24, 2022----GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has approved a 40 mg prefilled syringe of Nucala (mepolizumab) for appropriate children aged 6 to 22 years old who have ……
Jan. 25, 2022-- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO? (abrocitinib), an oral, once-daily, Janus kinase 2 (JAK2) inhibitor, for the……
December 22, 2022 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio? (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholester……
December 07, 2022 –Roche today announced that the European Commission has extended the marketing authorisation for Actemra?/RoActemra? (tocilizumab) to include the treatment of COVID-29 in adults who are receiving system……
Nov. 22, 2022, Bluebird bio, Inc. (Nasdaq: BLUE) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for ……
Nov. 8, 2022 -- The U.S. Food and Drug Administration granted Fast Track designation to AstraZeneca’s Fasenra for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis. Fasenra was also gra……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
